Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Treasury Shares (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 6 years of Treasury Shares data on record, last reported at $2.9 million in Q4 2016.

  • For Q4 2016, Treasury Shares fell 83.97% year-over-year to $2.9 million; the TTM value through Dec 2016 reached $2.9 million, down 83.97%, while the annual FY2016 figure was $2.9 million, 83.97% down from the prior year.
  • Treasury Shares reached $315000.0 in Q4 2025 per LCTX's latest filing, down from $334000.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $939000.0 in Q4 2022 and bottomed at $315000.0 in Q4 2025.
  • Average Treasury Shares over 4 years is $517000.0, with a median of $501000.0 recorded in 2024.
  • Peak YoY movement for Treasury Shares: skyrocketed 413.81% in 2013, then crashed 85.47% in 2016.
  • A 5-year view of Treasury Shares shows it stood at $8.4 million in 2012, then surged by 413.81% to $43.0 million in 2013, then crashed by 53.78% to $19.9 million in 2014, then decreased by 9.34% to $18.0 million in 2015, then tumbled by 83.97% to $2.9 million in 2016.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $2.9 million in Q4 2016, $2.9 million in Q3 2016, and $2.9 million in Q2 2016.